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Haloperidol differentially modulates prepulse inhibition and p50
suppression in healthy humans stratified for low and high gating
levels
Abstract
Schizophrenia patients exhibit deficits in sensory gating as indexed by reduced prepulse inhibition (PPI)
and P50 suppression, which have been linked to psychotic symptom formation and cognitive deficits.
Although recent evidence suggests that atypical antipsychotics might be superior over typical
antipsychotics in reversing PPI and P50 suppression deficits not only in schizophrenia patients, but also
in healthy volunteers exhibiting low levels of PPI, the impact of typical antipsychotics on these gating
measures is less clear. To explore the impact of the dopamine D2-like receptor system on gating and
cognition, the acute effects of haloperidol on PPI, P50 suppression, and cognition were assessed in 26
healthy male volunteers split into subgroups having low vs high PPI or P50 suppression levels using a
placebo-controlled within-subject design. Haloperidol failed to increase PPI in subjects exhibiting low
levels of PPI, but attenuated PPI in those subjects with high sensorimotor gating levels. Furthermore,
haloperidol increased P50 suppression in subjects exhibiting low P50 gating and disrupted P50
suppression in individuals expressing high P50 gating levels. Independently of drug condition, high PPI
levels were associated with superior strategy formation and execution times in a subset of cognitive
tests. Moreover, haloperidol impaired spatial working memory performance and planning ability. These
findings suggest that dopamine D2-like receptors are critically involved in the modulation of P50
suppression in healthy volunteers, and to a lesser extent also in PPI among subjects expressing high
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Schizophrenia patients exhibit deficits in sensory gating as indexed by reduced 
prepulse inhibition (PPI) and P50 suppression which have been linked to psychotic symptom 
formation and cognitive deficits. Although recent evidence suggests that atypical 
antipsychotics might be superior over typical antipsychotics in reversing PPI and P50 
suppression deficits not only in schizophrenia patients, but also in healthy volunteers 
exhibiting low levels of PPI, the impact of typical antipsychotics on these gating measures is 
less clear. To explore the impact of the dopamine D2-like receptor system on gating and 
cognition, the acute effects of haloperidol on PPI, P50 suppression, and cognition were 
assessed in 26 healthy male volunteers split into subgroups having low versus high PPI or P50 
suppression levels using a placebo-controlled within-subject design. Haloperidol failed to 
increase PPI in subjects exhibiting low levels of PPI and attenuated PPI in those subjects with 
high sensorimotor gating levels. Furthermore, haloperidol increased P50 suppression in 
subjects exhibiting low P50 gating and disrupted P50 suppression in individuals expressing 
high P50 gating levels. Independently of drug condition, high PPI levels were associated with 
superior strategy formation and execution times in a subset of cognitive tests. Moreover, 
haloperidol impaired spatial working memory performance and planning ability. These 
findings suggest that dopamine D2-like receptors are critically involved in the modulation of 
P50 suppression in healthy volunteers, and to a lesser extent also in PPI among subjects 
expressing high sensorimotor gating levels. Furthermore, the results suggest a relation 
between sensorimotor gating and working memory performance. 
 




Deficits in early information processing potentially leading to sensory overload have 
been considered a central feature of schizophrenia. It has been postulated that impaired 
cognition and positive symptoms of schizophrenia are related to deficient inhibition of early 
information processing (for a review see Braff et al. 2001). Two paradigms designed to assess 
central inhibition or gating are prepulse inhibition (PPI) of the acoustic startle response and 
suppression of the P50 event-related potential in a condition-test paradigm. PPI refers to the 
attenuation of the reflexive startle reaction elicited by an intense pulse stimulus when its 
presentation is preceded shortly (30 to 300 ms) by a weak prepulse stimulus (Graham 1975; 
Hoffman and Ison 1980). According to the “protection of processing” of Graham (1975, 1980, 
1992), the inhibitory effect of the prepulse upon subsequent pulse processing reflects the 
protection of the on-going processing of the antecedent prepulse against interference by the 
succeeding pulse. In practice, the magnitude of PPI is measured by the diminution of the 
startle response to the pulse stimulus due to the antecedent prepulse stimulus. The expression 
of PPI therefore represents an interplay of prepulse and pulse processing. This phenomenon is 
commonly considered as a form of sensorimotor gating, and can be readily demonstrated 
across species, from mollusc (Frost et al. 2003) to higher mammals including human (Braff et 
al. 2001). 
 
Similarly, in the P50 suppression paradigm two auditory stimuli are presented in 
succession at an interstimulus interval typically of 500 ms. The first stimulus (conditioning 
stimulus) not only produces an auditory evoked potential (AEP) approximately 50 ms after 
stimulation (P50 wave), but also activates gating processes, resulting in a suppression of the 
P50 AEP to the second stimulus (test stimulus). A number of studies have demonstrated that 
patients with schizophrenia exhibit deficits in both PPI (Braff et al. 2001, 1978) and P50 
suppression (Cadenhead 2002; Light and Braff 1999). In addition, low PPI and P50 
suppression levels have also been found in individuals with schizotypal personality disorder 
(Cadenhead et al. 1993, 2000, 2002) and in unaffected relatives of patients with schizophrenia 
(Clementz et al. 1998b; Kumari et al. 2005). Thus, it has been proposed that PPI and P50 
suppression are endophenotypic markers for schizophrenia spectrum disorders (Braff and 
Light 2005; Cadenhead et al. 2002). As such, these gating measures provide a unique 
opportunity to characterize the neurochemical basis of information processing deficits and the 
impact of antipsychotic treatments (Geyer et al. 2001). Indeed, it has recently been proposed 
that atypical antipsychotics might be superior over typical antipsychotics in normalizing PPI 
 
and P50 suppression deficits in schizophrenia patients (Adler et al. 2004; Becker et al. 2004; 
Kumari and Sharma 2002; Light et al. 2000). Nevertheless, a number of studies showed that 
PPI and P50 suppression are not associated in either healthy volunteers (Brenner et al. 2004; 
Light and Braff 2001b; Oranje et al. 2006c; Schwarzkopf et al. 1993) or schizophrenia 
patients (Braff et al. 2006b). Some relationship of P50 suppression to PPI was noted during 
the early part of the test session, when the process of habituation of the startle reflex is active 
(Oranje et al. 1999). Similarly, PPI and AEP gating in rats are not correlated (Ellenbroek et al. 
1999) and the two phenomena exhibit differential sensitivities to drug treatments (de Bruin et 
al. 1999b). These results derived from both humans and rodents suggest that different neural 
mechanisms underlie PPI and P50 suppression. 
 
Results of a number of cross-sectional studies suggest that patients treated for 
schizophrenia with atypical antipsychotics have similar PPI values as normal controls 
(Kumari et al. 1999, 2000, 2002; Leumann et al. 2002; Oranje et al. 2002b), whereas those 
treated with typical antipsychotics exhibited less PPI than did the control subjects (Grillon et 
al. 1992; Kumari et al. 1999; Oranje et al. 2002b). However, another study failed to replicate 
this distinction, finding that typical and atypical medications were equipotent in reversing the 
PPI deficit in schizophrenia patients (Quednow et al. 2005). On the other hand, several studies 
have failed to show PPI-enhancing effects of either typical or atypical medication in 
schizophrenia patients (Duncan et al. 2003a, 2003b; Mackeprang et al. 2002; Perry et al. 
2002), even though Duncan et al. (2003b) found an improvement of clinical symptoms with 
atypical medication. In contrast to these negative findings, a recent study found that an 
enhancement of PPI is associated with symptom reduction in patients treated for 
schizophrenia with either typical or atypical antipsychotic treatments (Meincke et al. 2004). 
Although it appears that atypical antipsychotics may be superior in normalizing PPI, the 
literature to date is inconclusive regarding the impact of antipsychotic medication on PPI. 
Consequently the impact of antipsychotic medication on PPI in schizophrenia patients 
remains uncertain. 
 
To explore further the effect of antipsychotic medication on PPI, a number of recent 
studies have investigated the possible differential effects of typical and atypical antipsychotics 
on PPI in healthy humans, rather than in patients. The use of normal healthy subjects with or 
without pharmacological challenge has the potential to overcome the confounding effects of 
previous medication exposure in patient populations. The wide range in severity of 
 
psychopathology and the generally non-random allocation of patients to treatment regimens 
(Hamm et al. 2001; Kumari and Sharma 2002) can be a considerable source of variability in 
results between studies. So far none of the studies investigating whether atypical 
antipsychotics increase PPI in normal subjects exhibiting a wide range of PPI yielded positive 
results (Barrett et al. 2004; Graham et al. 2001, 2004). However, two recent studies 
demonstrated that atypical antipsychotics such as clozapine or quetiapine increase PPI in 
clinically unaffected healthy subjects with low baseline PPI (Swerdlow et al. 2006; 
Vollenweider et al. 2006). Specifically, we have found that the mixed 5-HT2 / D2 receptor 
antagonist clozapine (Vollenweider et al. 2006), whereas Swerdlow et al. (2006) reported that 
quetiapine increased PPI at relatively brief SOAs of 20 and 30 ms in a similar group of 
healthy subjects with low PPI. On the other hand, two studies investigating the effects of the 
typical antipsychotic haloperidol found a disruption of PPI (Abduljawad et al. 1998; Oranje et 
al. 2004b) in healthy subjects, although the former study could not be replicated by that group 
(Abduljawad et al. 1999). Furthermore, one study (Kumari et al. 1998) reported that 
haloperidol disrupted PPI in normal smoking subjects but had no such effect in non-smoking 
subjects. In contrast to these findings, a number of other studies reported no effect of 
haloperidol on PPI in healthy volunteers (Abduljawad et al. 1999; Graham et al. 2001, 2004, 
2002; Kumari et al. 1998; Liechti et al. 2001). Similarly, chlorpromazine, a potent D2 receptor 
antagonist, was also found to have no effect on PPI (Barrett et al. 2004) in healthy volunteers. 
Taken together, these findings suggest that D2 receptor antagonists are without effect on, or 
tend to attenuate, PPI in normal subjects. 
 
The influence of antipsychotic medication on P50 suppression has been investigated in 
several patient studies. Schizophrenia patients treated with atypical antipsychotics had 
superior P50 suppression to those treated with conventional antipsychotic medication (Adler 
et al. 2004; Becker et al. 2004; Light et al. 2000). Especially patients receiving the atypical 
antipsychotic clozapine exhibited P50 suppression in the range of normal controls (Adler et 
al. 2004; Becker et al. 2004). In another study, Nagamato et al. (1996) showed that patients 
who were refractory to conventional neuroleptics, but were clinically responsive to clozapine 
also exhibited enhanced P50 suppression levels. On the other hand, Arango et al. (2003) could 
not show any difference in P50 suppression in schizophrenia patients who were treated with 
either olanzapine or haloperidol for three months. In contrast to the many studies exploring 
the effect of antipsychotic medication on P50 suppression in schizophrenia patients, few 
studies have investigated the effects of such treatment in healthy volunteers. Oranje et al. 
 
(2002a) found that a combination of haloperidol and ketamine disrupted P50 suppression in 
healthy volunteers, whereas the administration of ketamine alone had no effect on P50 gating. 
 
In addition to the well-documented deficits in PPI and P50 suppression, the occurrence 
of impaired cognitive performance, especially working memory, is a robust finding in 
schizophrenia patients (Badcock et al. 2005; Hutton et al. 1998; Weickert et al. 2000). 
Moreover, it has recently been demonstrated that those healthy human volunteers exhibiting 
low levels of PPI also show impaired performance in specific cognitive tasks relying on 
prefrontal cortical functioning (Bitsios et al. 2006; Giakoumaki et al. 2006). These authors 
concluded that superior ability in cognitive performance is related to more efficient early 
information processing. 
 
Based upon the above review of available literature, we hypothesised that haloperidol 
would not influence gating in those normal subjects with relatively high PPI/P50 suppression 
levels, but would increase PPI and/or P50 suppression in those normal subjects with low 
gating performance at baseline. Furthermore, we predicted that sensory and/or sensorimotor 
gating levels correlate with cognitive performance, as reported previously (Bitsios et al. 2006; 
Giakoumaki et al. 2006), and that cognitive performance is influenced by the administration 
of haloperidol. To test these hypotheses, we measured the effects of acute treatment with the 
dopamine D2 receptor antagonist haloperidol on PPI and P50 suppression in a group of 
healthy volunteers, who were stratified according to low or high placebo gating levels, based 
upon our study design for investigating the effect of clozapine on PPI in normal volunteers 
(Vollenweider et al. 2006). A subset of tests from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) was used to assess attentional set-shifting, working memory, 
and executive functioning and their relationship to haloperidol treatment and sensory gating. 
 
METHODS AND MATERIALS 
Subjects 
Thirty-four healthy male volunteers were recruited by advertisement. Due to the 
occurrence of gender-differences in PPI (Swerdlow et al. 1996), only male subjects were 
included. The study was approved by the ethics committee of Zurich canton and Swissmedic. 
All subjects gave their informed written consent, were without a history of mental (according 
 
to DSM IV, axis I and II) and neurological disorders, had no history of an axis I disorder 
amongst their first-degree relatives, and were free of any medication for at least three weeks 
prior to the experiment. To ascertain the subjects’ mental status, all subjects were screened by 
the DIA-X diagnostic expert system (Wittchen and Pfister 1997), a semi-structured 
psychiatric interview. Subjects with personal or family (first-degree relatives) histories of 
major psychiatric disorders were excluded. Assessment of the use of legal and illegal drugs 
was done using a structured interview. Furthermore, all the volunteers underwent clinical 
examination which included electrocardiography and blood analysis. All subjects were 
instructed to abstain from drinking alcohol for at least 24 hours before each test session, not to 
drink any caffeine-containing beverages on the day of testing, and to keep their usual smoking 
habits. Smoking was not allowed from one hour prior to the recording session. From the 
original 34 subjects agreeing to participation in the study, two subjects were excluded due to 
declaration of substance abuse, and three subjects were excluded because physical 
examination indicated a contraindication for taking haloperidol. Additionally, three volunteers 
withdrew from the study after the first test day. All remaining 26 subjects completed the 
CANTAB measurement. The PPI data of three subjects were rejected because no distinct 
startle reaction could be elicited (non-responders, mean startle amplitude on pulse alone trials 
<10 μV in the presentation block relevant for %PPI calculation) and four subjects declined to 
continue electrophysiological recordings after completing the PPI assessment, thus resulting 
in 19 complete datasets (PPI, P50, CANTAB), with only PPI and CANTAB data from four 
subjects, and only P50 and CANTAB data from three subjects. Hearing was evaluated in all 
subjects, using a standard computerized whispered voice test (for a review see Pirozzo et al. 
2003). No subjects were excluded due to hearing difficulties. Subject demographics are 








In a double-blind, placebo-controlled within-subjects design, participants received 
haloperidol (2 mg per 70 kg body-weight, dose ranged from 1.8 to 2.7 mg) or placebo (saline 
solution) in a balanced and random sequence, intravenously on two experimental days, 7 to 14 
days apart. Haloperidol (Haldol) was obtained from Janssen (Janssen-Cilag AG, Zug, 
Switzerland). On each experimental day, 30 minutes after drug administration, subjects 
underwent the PPI assessment followed by a short break prior to the P50 suppression session. 
After detaching all electrodes used in the electrophysiological recordings, subjects underwent 
neuropsychological testing using a subset of CANTAB tests. 
 
PPI and P50 Suppression Session Definition 
The PPI test session was composed of a mixture of pulse-alone trials, prepulse-pulse 
trials and trials in which no discrete stimulus other than the constant background noise was 
presented (denoted hereafter as ‘no-stimulus’ or ‘NS trials‘). All stimuli (background noise, 
pulses and prepulses) used in the experiment consisted of broadband white noise. The 
intensity of the background noise was set at 70 dBA. Pulse stimulus intensity was set at 115 
dBA and the prepulse stimulus intensity at 86 dBA. The stimulus duration was 40 ms for pulse 
stimuli and 20 ms for prepulse stimuli. Rise and fall time of the stimuli were less than 1 ms. 
The four SOA between the prepulse and pulse stimuli on prepulse-pulse trials were 60, 120, 
240 and 2000 ms (SOA 60, SOA 120, SOA 240 and SOA 2000). The session began with a 2 
min period of acclimatization to the background noise, followed by the presentations of 69 
discrete trials according to a variable inter-trial interval (ITI) ranging from 9 to 18 s (mean= 
13.7). The first and last block consisted of five consecutive pulse-alone trials. The middle 
block consisted of 60 trials, i.e., 10 trials of each of the six conditions (pulse-alone, prepulse-
pulse combinations and NS trial). The sequence of presentation was pseudo-randomised. The 
PPI test session lasted approximately 17 min. 
 
The P50 suppression test session was composed of 80 pairs of auditory clicks with a 
500 ms interclick interval presented every 8-12 s (mean= 9.8). Stimuli consisted of 86 dBA 
white noise with a duration of 1 ms. The P50 suppression session lasted for approximately 15 
min. 
 
Apparatus, Data Recording and Data Processing 
Electromyographic (EMG) and electroencephalographic (EEG) recordings were 
performed in the same sound-proof EEG-room. The subjects were informed that the first 
 
experiment (PPI) was intended to investigate simple blink reflexes in the presence of 
broadband white noise, and the second experiment (P50 suppression) was for the 
investigation of changes in brain activity upon auditory stimulation. They were informed that 
the stimuli themselves did not pose any risk to their hearing. Subjects were then asked to sit 
comfortably in a chair, to relax and stay awake while looking at a blank wall approximately 2 
m away. 
 
Acoustic stimuli were generated by EMG-SR (San Diego Instruments, San Diego, CA, 
USA) and presented binaurally through headphones (TDH-39-P, Maico, Minneapolis, MN, 
USA). EEG recordings were made from 64 scalp locations (10-20 system) using the 
ActiveTwo system (Biosemi, The Netherlands). The horizontal electro-occulogram (EOG) 
was recorded from electrodes attached on the outer canthus of each eye. Similarly, vertical 
EOG was recorded from electrodes attached infraorbitally and supraorbitally to the left eye. 
Additionally, startle reaction was assessed from two electrodes placed below the right eye 
over the orbicularis oculi muscle. All electrodes were active silver/silver-chloride electrodes 
and the offset of all electrodes was below 25 µV. The trigger-signal to mark stimulus-onset 
was sent over the parallel port of the stimulus computer to the recording unit. The system 
recorded continuously over the whole session using a sampling rate of 4096 Hz for the PPI 
paradigm and 512 Hz for the P50 suppression paradigm. Analyzer (Brainvision®, Germany) 
was used to pre-process the recorded data. 
 
For the PPI paradigm, the two electrodes located over the orbicularis oculi muscle 
were referenced bipolarly, resulting in a single EMG channel. EMG activity was band-pass 
filtered (30–500 Hz), down-sampled to 1000 Hz to reduce the amount of data, and then 
rectified. Segmentation was performed from 50 ms prior to the onset of the relevant stimulus 
(the prepulse in prepulse-pulse trials, respectively the pulse in pulse-alone trials) to 2250 ms 
after stimulus onset. The segmented data were exported for quantitative analysis. The EMG 
record of each and every trial was separately scored using the WindowsTM based software 
emgBLINK version 1.2 (CST, Switzerland). Before scoring, the EMG was smoothed with a 
time constant of 5 ms. Baseline amplitude was calculated by the mean response amplitude of 
the first 50 ms before any stimulus onset. Stimulus response amplitudes were assessed as peak 
response minus baseline value of the respective trial. Peak response was defined as the 
highest reaction in the time-window between stimulus onset to 150 ms after stimulus onset. In 
pulse-alone trials and prepulse-pulse trials reaction to the pulse was scored. Additionally, in 
 
the prepulse-pulse trials with a SOA of 2000 and 240 ms reaction to the prepulse was scored. 
Response amplitudes on NS trials were scored as peak response sample between 51 and 201 
ms minus baseline value of the respective trial. Every trial was also examined for sign of 
spontaneous eye-blinks in the scoring windows, and other possible signs of corrupted EMG 
signal and if present the trial was excluded. 
 
For the P50 suppression paradigm, data were band-pass filtered (1.5–70 Hz, 50 Hz 
notch filter). Independent Component Analysis (ICA) was used to remove artefacts due to eye 
movement and blinks. Then, EEG data were re-referenced to the average of the 64 scalp 
electrodes (average reference) and segmented from 800 ms before to 1000 ms after the first 
click. The resulting 80 segments were visually screened for any sign of corrupted EEG and, if 
present, excluded from further processing. The artefact-free segments were then re-segmented 
50 ms before click-onset to 300 ms after click-onset separately for both stimulus conditions 
(click 1 and click 2) and then averaged. The P50 component of the AEP was identified and 
scored as described by Nagamoto et al. (1989): The P50 peak was identified as the most 
positive deflection 40 to 80 ms after stimulus presentation. The P50 amplitude was scored as 
the absolute difference between the P50 peak and the preceding negative trough. Only data 
from the Cz location were analyzed where the maximum activity for the P50 AEP was 
expected (Clementz et al. 1998a). 
 
Assessed Parameters 
For the PPI paradigm the following startle measures were examined: Pulse-alone- and 
prepulse-elicited reaction; the mean startle reactivity elicited by the pulse-alone stimulus in 
each of the three pulse blocks was calculated for each subject. The same was conducted 
separately in regard to the prepulse in the prepulse-pulse trials (SOA 240 and 2000 ms). The 
mean reactivity score obtained on NS trials was also calculated and included as a control 
condition. Prepulse Inhibition; percentage PPI (%PPI) was calculated for each SOA by the 
formula: [1 – (amplitudeprepulse-pulse) / (amplitudepulse-alone (block2))] × 100%. Habituation; the 
reduction of the startle amplitudes between the first and last block was calculated according to 
the formula: [1 – (amplitudepulse-alone (block3)) / (amplitudepulse-alone (block1)] × 100%. Sensitization; 
percentage scores were calculated for the mean amplitude of trial 2 to 5 in relation to the first 
trial according to the formula: [mean amplitudetrial 2-5 / amplitudetrial 1] × 100%. 
 
 
For the P50 suppression paradigm the following ERP measures were examined: P50 
amplitudes; P50 amplitude evoked by the first (s1) and second click stimulus (s2). P50 
suppression; percentage P50 suppression was calculated by the formula: [1 – (amplitudes2) / 
(amplitudes1)] × 100%  
 
As summarized briefly below, seven tests of the CANTAB were administered using an 
IBM-compatible PC with a touch screen monitor (Elo IntelliTouch). More technical 
descriptions of the tasks can be found on the Cambridge Cognition’s website: 
www.cantab.com. Motor screening (MOT): All subjects were introduced to the touch-screen 
procedure by completing a simple motor screening task consisting of touching the centre 
point of flashing crosses on the screen as soon as possible after its presentation (results not 
shown). Rapid Visual Information Processing (RVP): This task is a visual continuous 
performance task using pre-defined sequences of three digits presented at a rate of 100 per 
minute so as to assess sustained attention over a period of 4 minutes. RVP performance was 
assessed by total correct responses to target sequences (total hits), the sensitivity to detect 
target sequences (A’), and the mean latency to target sequences. Pattern recognition memory 
(PRM): This task assesses visual recognition memory in a 2-choice forced discrimination 
paradigm. Performance was indexed by the mean latency to the correct answer, and the 
percentage of correct hits. Stockings of Cambridge (SOC): This test assesses the subject's 
spatial planning ability, based upon the 'Tower of London' task (Shallice 1982). The total 
number of problems solved in the minimum possible number of moves, the number of moves 
to reach criterion, initial thinking time and subsequent thinking time were all assessed. Spatial 
Working Memory (SWM): This is a test of spatial working memory and strategy performance. 
The subject had to find a blue 'token' in each displayed box, whilst not returning to boxes in 
which a blue token had already been found. Performance was indexed by a strategy score, 
which represents the number of times the subject begins a new search with the same box. A 
high score represents poor use of this strategy and a low score equates to effective use. 
Furthermore, the total number of errors and between errors (searching a token in a box where 
one had already been found) was assessed. Intra/Extradimensional attentional set shifting 
(ID/ED): This is a test of rule acquisition and reversal, featuring visual discrimination and 
attentional set shifting, analogous to the Wisconsin Card Sorting Task (Heaton, 1981). 
Performance was assessed by the number of trials to reach criterion, the total number of errors 
(adjusted to the number of completed stages), the errors made up to the extra-dimensional 
shift (Pre-ED errors) and the errors made at the extra-dimensional stage of the task (EDS 
 
errors). Spatial recognition memory (SRM): This task tests visual spatial memory in a 2-
choice forced discrimination paradigm. Performance was indexed by the mean latency to 
correct answers, and percent of correct hits of a maximum of 20. 
 
Statistical Analysis 
All statistical analyses were conducted using the statistical software Statistica 7 for 
Windows (Statsoft® Inc., OK, USA). To test whether haloperidol had a differential effect on 
subjects with low or high placebo gating measures, subjects were grouped by a median-split 
procedure into low and high performers. For the PPI paradigm, this median spilt was based on 
the results of %PPI in the SOA 60 placebo condition (medianPPI= 61.6%). Similarly, for the 
P50 suppression paradigm the median split was applied using the scores at %P50 suppression 
in the placebo condition (medianP50= 63.8%). An alternate approach of segregation by mean 
split (meanPPI= 63.2%; meanP50= 51.0%) was considered, and was found to result in identical 
PPI grouping, and virtually the same P50 groups, differing only by two subjects. As 
summarized in Table 1, the low and high PPI and P50 groups did not differ in age, smoking 
habits, or IQ as measured by the Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B) (Lehrl 
1999). 
 
Startle amplitudes were analysed using repeated measures analysis of variance 
(ANOVA) with block (1 to 3) and treatment (placebo vs. haloperidol) as within-subject 
factors and group (low vs. high) as between-subject factors. Similarly, %PPI values were 
subjected to a 4 × 2 × 2 (SOA × treatment × group) repeated measures ANOVA. Analysis of 
%habituation was performed analogously as above, but with treatment as within-subject 
factor and group as between-subject factor, separately for PPI and P50 groups. A three-way 
ANOVA (SOA and treatment as repeated measures and group as between factor) for 
prepulse-elicited reactions was performed including the NS, SOA 240 and SOA 2000 
conditions only, since these SOAs allow the use of the same scoring window size (150 ms) as 
had been used for the scoring of all the other trial types. Amplitude and latency of the P50 
component were likewise analysed using a three-way ANOVA with the factors stimulus-type 
(conditioning vs. test stimulus), group, and treatment. The %P50 suppression data were 
analysed by a 2 × 2 (treatment × group) repeated measures ANOVA. 
 
Potential commonalities between the PPI and P50 suppression paradigm were 
investigated by Pearson correlations between amplitude and suppression values of the two 
 
gating paradigms. Two-way ANOVAs with group and treatment were used to examine the 
effect of haloperidol on the performance of RVP, PRM, SRM and ID/ED CANTAB tasks. 
For the SOC and SWM CANTAB tasks, the additional factor “difficulty” was introduced. For 
significant effects, the effect size, expressed as partial eta-squared (ηp2), was also calculated. 
To assess relationships between gating measures and CANTAB scores, Pearson correlations 
were calculated. Due to the high number of correlations examined, the significance level for 
Pearson correlations was set to p<0.0008. For the other statistical tests the significance level 
was set to p<0.05. 
 
RESULTS 
Prepulse Inhibition Paradigm 
The results are summarized in Table 2. There was no significant difference in startle 
amplitude between the two groups, nor any change of startle induced by haloperidol. As 
expected, startle amplitude significantly diminished over the three blocks [main effect of 
block; F(2,42)=31.58, p<0.001, ηp2=0.60]. However, %habituation and %sensitization did not 
differ between the low and high PPI or P50 suppression groups, nor were they influenced by 
haloperidol. 
 
Due to the median splitting of subjects into low and high sensorimotor gaters, %PPI 
was significantly different between the two groups [main effect of group; F(1,21)=7.32, 
p<0.05, ηp2=0.26]. Moreover, there was a significant main effect of SOA [F(3,63)=58.12, 
p<0.001, ηp2=0.73] and a significant SOA x group interaction [F(3,63)=4.4, p<0.01, 
ηp2=0.17]. No significant main effect of treatment was found (Fig. 1). Results of the ANOVA 
revealed a non-significant treatment × group interaction [F(1,21)=2.85, p=0.11). Nevertheless, 
based on our a priori hypothesis that haloperidol would modulate PPI differentially in 
subjects exhibiting either low or high baseline PPI levels, two-way ANOVAs restricted to the 
inhibitory SOAs (60, 120 and 240 ms) were performed separately for either the low and high 
PPI groups. Results of these analyses approached statistical significance for main effect of 
treatment in the high PPI group [F(1,11)=4.76, p=0.05, ηp2=0.30], but not in the low PPI 
group, indicating a reduction of PPI in the high group upon haloperidol treatment. 
Furthermore, there was a significant main effect for SOA in both groups [high group: 
F(2,22)=19.83, p<0.001, ηp2=0.64; low group: F(2,20)=8.65, p<0.01, ηp2=0.46]. For the 
examination of the impact of test order (active drug test day 1 vs. test day 2), repeated 
 
measures ANOVA with the factors group, SOA, treatment, and test order were performed. 
This analysis revealed neither a significant main effect of test order nor any interactions 
between test order and the other factors. Therefore, in order to optimise the statistical power, 
the factor “test order” was dropped from the final analysis. Pearson correlations revealed no 
relationship between the absolute dose of haloperidol administered and change in %PPI upon 
treatment for any SOA. 
 
Analysis of prepulse-elicited reaction revealed no significant main effect of treatment, 
and no effect of group, but did reveal a significant main effect of trial type [F(2,42)=4.99, 
p<0.05, ηp2=0.19]. Fisher’s LSD post-hoc testing on SOA showed that the effect of trial type 
is a consequence of the two prepulse conditions being different from the NS condition (ppost-
hoc<0.05 for SOA 240 and ppost-hoc<0.01 for SOA 2000), whilst being similar to each other 
(p=0.93), indicating that the prepulse stimulus elicited a measurable response. 
 
 
Figure 1. Percentage prepulse inhibition at the four prepulse–pulse conditions (SOA: 60, 120, 240, and 2000 ms) 




P50 Suppression Paradigm 
As summarized in Table 2, there was a significant main effect of stimulus type 
(conditioning vs. test stimulus) [F(1,20)=44.83, p<0.001, ηp2=0.69], indicating the occurrence 
of P50 suppression. Moreover, the interaction between stimulus type and group was 
significant [F(1,20)=5.27, p<0.05, ηp2=0.21]. Fisher’s LSD post-hoc revealed that the 
amplitude in the placebo condition to the test (p<0.05) but not to the conditioning (p=0.97) 
stimulus was different between the two groups. Therefore, the anticipated distinction of P50 
suppression between the high and low group was due to differences in the amplitudes elicited 
by the test stimulus, rather than the conditioning stimulus. Although there was no main effect 
of treatment, nor was there a significant interaction between treatment and stimulus type, the 
3-way interaction between treatment, stimulus type, and group [F(1,20)=9.8, p<0.01, 
ηp2=0.33] was significant. 
 
As forced by the splitting of the subject group into low and high P50 gaters, analysis 
of P50 suppression, as indexed by percent suppression, revealed a significant main effect of 
group [F(1,20)=18.6, p<0.001, ηp2=0.48]. Although there was no significant main effect of 
treatment, the interaction between treatment and group attained significance [F(1,20)=24.7, 
p<0.001, ηp2=0.55] (Fig. 2), indicating the treatment effects differed between the two groups. 
Examination of the influence of test order revealed neither a significant main effect of test 
order nor any interactions with the other factors (group, treatment). Pearson correlations 
revealed no relationship between the absolute dose of haloperidol administered and change in 
P50 suppression. 
 
There were no significant correlations among any of the parameters assessed 
(%suppression, %startle habituation, startle amplitudes, P50 amplitudes, P50 latencies) 
between the two gating paradigms (PPI & P50 suppression), either within or between the two 
treatment conditions. There was an overlap of five subjects (26%) for the highPPI-highP50 
group-combination and of seven subjects (37%) for the lowPPI-lowP50 group-combination. The 
χ2 test of association revealed no significance (p=0.26). 
 
§ 
Figure 2. Percentage P50 suppression in the low (○) and the high (□) P50 subgroups during placebo and 
haloperidol treatment. Error bars refer to ± SEM. 
 
Neuropsychological Testing 
The results of CANTAB testing with respect to the PPI group formation are 
summarized in Table 3. Strategy in the SWM task was significantly better in the high than in 
the low PPI group [F(1,21)=7.82, p<0.05, ηp2=0.27]. Moreover, Pearson correlation analysis 
revealed a significant correlation between strategy score and %PPI at SOA60 in the placebo 
condition [R=-0.65, p<0.0008], indicating the presence of superior strategy formation in 
subjects with high PPI values (Fig. 3). In the SOC task mean moves to solve the problem 
[F(1,21)=5.49, p<0.05, ηp2=0.21] and problems solved in minimum moves [F(1,21)=5.14, 
p<0.05, ηp2=0.20] were lower and mean subsequent thinking time [F(1,21)=6.18, p<0.05, 
ηp2=0.23] was shorter in the high PPI group. In the other CANTAB tasks no difference was 
found with respect to the low and high PPI group. Treatment with haloperidol impaired 
spatial working memory performance as revealed by higher error rates [F(1,21)=12.26, 
p<0.01, ηp2=0.37 (between errors); F(1,21)=11.06, p<0.01, ηp2=0.35 (total errors)] and by 
reduced strategy formation [F(1,21)=7.76, p<0.05, ηp2=0.27] in the SWM task. Although 
response latency in the SRM task [F(1,21)=4.74, p<0.05, ηp2=0.18] and initial thinking time 
 
in the SOC task [F(1,21)=5.98, p<0.05, ηp2=0.22] were reduced by haloperidol, there was no 
effect of the treatment on the general accuracy in those tasks. Main effects for difficulty were 
significant in the SOC and SWM task (see Table 3). 
 
A corresponding analysis of the CANTAB data was conducted with respect to the 
grouping by P50 performance. The high and low P50 suppression subjects did not 
significantly differ in cognitive performance in any of the CANTAB tests. The main effects of 
haloperidol treatment on CANTAB scores were almost identical in the P50 group as in the 
PPI group, as expected due to the near identity of the two groups; haloperidol increased the 
error rates [F(1,20)=9.38, p<0.01, ηp2=0.32 (between errors); F(1,20)=8.8, p<0.01, ηp2=0.31 
(total errors)], and reduced the strategy score [F(1,20)=5.56, p<0.05, ηp2=0.22] in the SWM 
task. Furthermore, there was a reduction of the initial thinking time in the SOC task upon 
haloperidol treatment [F(1,20)=7.04, p<0.05, ηp2=0.26]. 
 
 
Figure 3. Correlation of percentage prepulse inhibition at the SOA of 60 ms in the placebo condition and 




The present study was designed to test the hypothesis that the typical antipsychotic 
and dopamine D2-like receptor antagonist haloperidol differentially modulates PPI and P50 
suppression in healthy human subjects stratified into groups with high and low gating 
performance. Haloperidol did not increase PPI in subjects exhibiting low placebo 
sensorimotor gating levels, but attenuated PPI in the group of subjects exhibiting high PPI in 
the placebo condition. The influence of haloperidol on P50 suppression depended critically on 
placebo P50 gating levels of the individual subject; while haloperidol increased P50 
suppression in those subjects with low P50 suppression levels in the placebo condition, it 
reduced P50 suppression in individuals with high placebo P50 gating levels. Compared to 
individuals in the high PPI group, the group which exhibited low PPI levels had worse 
strategy formation in the SWM task. Furthermore, the strategy score correlated with %PPI at 
SOA60 in the placebo condition. In the SOC task, the low PPI subjects needed more moves, 
solved fewer problems correctly within the minimum number of moves, and had increased 
subsequent thinking time. 
 
Prepulse Inhibition: 
In contrast to results of our previous study (Vollenweider et al. 2006), which showed 
an enhancing effect of the atypical antipsychotic clozapine on PPI in subjects exhibiting low 
baseline sensorimotor gating levels, haloperidol failed to improve PPI in the low performing 
group. This finding is in accordance with previous work investigating the effect of haloperidol 
on PPI in healthy volunteers (Abduljawad et al. 1999, 1998; Barrett et al. 2004; Graham et al. 
2001, 2004, 2002; Kumari et al. 1998; Liechti et al. 2001; Oranje et al. 2004b). It is 
noteworthy that the haloperidol doses and SOA employed in most of these earlier studies 
were similar to the present study (Abduljawad et al. 1999; Barrett et al. 2004, 2001, 2004, 
2002; Kumari et al. 1998; Liechti et al. 2001). Thus, it appears that stratification of normal 
subjects into low and high PPI performers did not reveal the predicted enhancement of PPI by 
haloperidol in normal subjects with relatively low PPI levels. This negative finding is in 
accordance with several studies in schizophrenia patients, which showed that atypical 
antipsychotic medication had no PPI-enhancing effect (Grillon et al. 1992; Kumari et al. 
1999; Oranje et al. 2002b); (Duncan et al. 2003a, 2003b; Mackeprang et al. 2002; Perry et al. 
2002). It should be noted that the healthy subjects in our earlier study (Vollenweider et al. 
2006) had lower PPI levels (meanSOA60 = 8.8± 3.3%) than did the low PPI group in the present 
study (meanSOA60 = 43.8± 13.8%). Thus, it remains possible that haloperidol might have 
 
enhanced PPI in subjects with extremely low PPI performance. Moreover, treatment with 
haloperidol significantly reduced PPI in subjects with high placebo %PPI levels (meanSOA60 = 
80.9± 9.6%). This finding is in accordance with two other studies reporting a haloperidol-
induced reduction of %PPI in subjects with comparable high baseline PPI performance 
around 70% (Abduljawad et al. 1998; Oranje et al. 2004b). In addition, a number of studies 
(Abduljawad et al. 1999; Graham et al. 2001, 2004, 2002; Kumari et al. 1998; Liechti et al. 
2001) found no effects of haloperidol on PPI in subjects expressing lower baseline PPI levels 
(40-60%). Therefore, we can conclude that the effect of haloperidol on PPI is dependent on 
individuals’ baseline gating levels. In contrast to the present findings with haloperidol, the 
mixed 5HT/ D2 receptor antagonists/antipsychotics clozapine (Vollenweider et al. 2006) and 
quetiapine (Swerdlow et al. 2006) have been reported to increase PPI in subjects exhibiting 
relatively low PPI levels. We speculate that the somewhat discrepant results between PPI 
studies using typical and atypical neuroleptics may indicate that serotonergic in addition to 
dopaminergic mechanisms may contribute to the modulation of PPI in clinically unaffected 
healthy subjects with low PPI levels. 
 
P50 suppression: 
Results of the present study show an enhancing effect of haloperidol on P50 
suppression in subjects exhibiting low placebo suppression levels and an opposite (disruptive) 
effect in individuals showing high P50 suppression performance in the placebo condition. In 
contrast to this finding in healthy human individuals, in schizophrenia patients - although 
showing characteristically poor P50 suppression levels - typical antipsychotics such as 
haloperidol do not have an enhancing effect on P50 gating. Thus, dopamine D2 receptor 
antagonism alone seems insufficient to normalize P50 gating in schizophrenia patients, in 
contrast to effects seen in healthy subjects with low P50 suppression levels. Indeed, several 
earlier studies have shown that schizophrenia patients treated with typical antipsychotic 
medication exhibited significantly less P50 suppression than did patients receiving atypical 
antipsychotics (Adler et al. 2004; Becker et al. 2004; Light et al. 2000). Specifically, patients 
receiving clozapine (Adler et al. 2004; Tandon and Jibson 2003) or olanzapine (Berg and 
Balaban 1999) had superior suppression levels relative to those treated with typical 
antipsychotic medication. Moreover, Nagamato et al. (1996) reported that schizophrenia 
patients, who therapeutically responded to clozapine after one month of treatment also 
showed enhanced P50 suppression levels. Arango and colleagues (2003) showed that three 
months’ treatment with haloperidol did not result in an enhancement in P50 suppression. 
 
However, in that same study, treatment with the atypical antipsychotic olanzapine also failed 
to elevate P50 gating. 
 
In contrast to the preponderance of studies of P50 suppression in patients with 
schizophrenia treated with typical neuroleptics, we found that haloperidol perturbed P50 
suppression in healthy volunteers. To our knowledge no earlier studies have shown an effect 
of typical antipsychotic medication, specifically haloperidol, on P50 suppression, either in 
healthy volunteers or in schizophrenia patients. In view of this discrepancy, the question 
arises as to the extent of the involvement of dopamine neurotransmission in the regulation of 
P50 gating. Dopaminergic involvement in P50 suppression has been examined in several 
human and animal studies. For example, d-amphetamine, an indirect dopaminergic and 
noradrenergic agonist, disrupts P50 suppression in healthy volunteers (Light et al. 1999), 
indicating that potentiation of catecholamine neurotransmission interferes with P50 gating. 
Animal models of N50 suppression, the rodent analogue of P50 in humans, also denoted as 
N40, have also implicated monoaminergic neurotransmitter systems in the modulation of P50 
suppression. As in humans, acute d-amphetamine reduced gating of the N40 component in 
rodents (Adler et al. 1986; de Bruin et al. 1999a). Thus, Adler and colleagues (1986) conclude 
that “catecholamines have significant modulatory effects on the gating, amplitude, and 
latency of P50 in humans and rats”. An amphetamine-induced increase specifically in 
noradrenergic transmission may mediate disruption of P50 suppression, since yohimbine, an 
α2 receptor antagonist that enhances the release of noradrenaline by a presynaptic mechanism, 
also disrupts P50 suppression in humans (Adler et al. 1994) and N40 suppression in animals 
(Stevens et al. 1993). Stevens and colleagues (1993) conclude that a yohimbine-induced 
increase in endogenous noradrenergic tone resulted in disrupted sensory gating. This 
disruption could not be reversed by the D1 antagonist SCH 23390. Furthermore, Oranje et al. 
(2004a) showed that the dopamine precursor L-Dopa and the D2 receptor agonist 
bromocriptine both reduced the amplitudes of the P50 component evoked by the conditioning 
and the test stimuli equally, consequently not changing P50 suppression per se, providing 
further evidence that noradrenaline is more important than dopamine in the regulation of P50 
suppression. 
 
Taken together, the results of studies investigating monoaminergic influence in the 
regulation of P50 suppression and the findings that typical antipsychotic medication do not 
enhance P50 gating in patients, call the putative role of dopamine in the modulation of P50 
 
suppression into question. This scenario stands in contrast to our present findings, which 
demonstrated an elevation or disruption of P50 suppression by haloperidol, depending on the 
individual baseline P50 gating levels. In support of our present results, Adler et al. (1986) 
demonstrated that the effect of haloperidol on N50 gating in rats depended highly on the 
initial state of individual animals; N50 suppression in those rats with high baseline 
suppression levels was unaffected by haloperidol, but was greatly enhanced by haloperidol in 
those rats showing consistently poor suppression values. Furthermore, Adler et al. (1986) 
demonstrated that the disruptive effect of d-amphetamine on P50 gating could be reversed by 
haloperidol. Moreover, Oranje et al. (2002a) found a disruptive effect of haloperidol and 
ketamine combined treatment on P50 suppression in humans, whereas the administration of 
ketamine alone was without effect. However the study by Adler et al. (1986) was based on a 
small number of animals, while the study of Oranje et al. (2002a) lacked a haloperidol-only 
condition, and so cannot be directly compared with the present design.  
 
We speculate that the finding of the differential impact of typical antipsychotic 
medication on P50 suppression between schizophrenia patients and the present results in 
healthy volunteers might reflect unequal contributions of dopamine D2 receptors in the 
modulation of P50 gating between patients with schizophrenia and healthy volunteers. There 
is some precedent for such a distinction; studies involving patients with schizophrenia or 
bipolar disorder revealed that, whereas P50 suppression deficits in bipolar patients are 
normalized by treatment with (typical) neuroleptics and lithium carbonate, there was no such 
normalization in the schizophrenia patient group (Adler et al. 1990; Franks et al. 1983). 
Furthermore, the correlation between P50 suppression and the severity of psychosis (Baker et 
al. 1987), and the finding that disrupted P50 suppression occurs during acute mania, but 
returns to normal values with abatement of the acute psychosis (Franks et al. 1983), indicate 
that reduced P50 suppression is state-dependent in bipolar disorder (Adler et al. 1990; Baker 
et al. 1987; Franks et al. 1983). In contrast, disrupted P50 gating in schizophrenia spectrum 
disorder seems to reflect a trait deficit. Thus, our results in healthy volunteers add to what is 
already known about differences in P50 suppression among psychiatric conditions (Adler et 
al. 1990; Baker et al. 1987; Franks et al. 1983). 
 
In line with previous studies which investigated the relationship between PPI and P50 
suppression in healthy volunteers (Brenner et al. 2004; Light and Braff 2001a; Oranje et al. 
2006b; Schwarzkopf et al. 1993), we did not find any significant correlations between those 
 
two gating paradigms. Although in the present study PPI and P50 suppression were assessed 
in separate but immediately successive recording sessions, also no direct relationship has been 
found in studies which measured PPI and P50 suppression in a single recording session 
(Brenner et al. 2004; Light and Braff 2001c; Oranje et al. 2006a). However, Oranje et al. 
(1999) reported a significant positive correlation between PPI and P50 suppression early in 
testing, when habituation of the startle reflex is taking place. Furthermore, Braff et al. (2006a) 
also reported weak positive correlation between the two measures of gating. Although there 
was an overlap of 7 subjects (37%) for the lowPPI-lowP50 group-combination in the present 
study, the χ2 test of association did not reach statistical significance. 
 
Relationship between neuropsychological performance and prepulse inhibition: 
As shown in Table 2, subjects with low and high PPI differed significantly in the 
spatial working memory (SWM) and planning task (SOC) of the CANTAB. High PPI levels 
predicted superior strategy formation and execution times. In particular, we found a 
correlation between the individuals’ skill to form an appropriate search strategy in the SWM 
task and the magnitude of PPI (see Fig. 3). In the SOC task, subjects with low PPI 
performance had prolonged subsequent thinking times, which may reflect a tendency to act 
before the strategy is fully formed, or may reveal the formation of less efficient strategies. 
Furthermore, the low PPI subjects required more moves per problem and consequently solved 
fewer problems in the minimum number of moves. A very similar pattern of results has been 
found recently in healthy volunteers (Bitsios et al. 2006; Giakoumaki et al. 2006), leading 
Bitsios et al. (2006) to conclude that improved early information processing, as indexed by 
high PPI levels, is associated with superior abilities in strategy formation and execution times. 
 
With respect to the present findings, it is of great importance that the performance in 
the SWM and SOC tasks relies on the integrity and efficiency of prefrontal cortical function. 
Patients with frontal lobe lesions are impaired in their ability to form efficient search 
strategies in the SWM task (Owen et al. 1996; Owen and Downes 1990). Moreover, Owen 
and Downes (1990) found that patients with frontal lobe damage required more moves to 
solve the problem, and also exhibited prolonged subsequent thinking time in the SOC task. 
Our finding that high and low PPI subjects differ in their performance of tasks involving the 
prefrontal cortex supports the putative role of the prefrontal cortex in the modulation of PPI, a 
claim which is consistent with previous animal and human studies (Bubser and Koch 1994; 
Hazlett et al. 1998; Hazlett and Buchsbaum 2001; Kumari et al. 2003; Zavitsanou et al. 1999). 
 
 The effect of haloperidol on neuropsychological performance: 
The overall performance in the SWM task was impaired by haloperidol, as measured 
by reduced strategy formation and increased error rates. There is considerable evidence that 
mesotelencephalic dopamine systems play a crucial role in cognitive processes involving the 
prefrontal cortex. Brozoski et al. (1979) demonstrated that 6-hydroxydopamine lesions of the 
prefrontal cortex in rhesus monkeys impaired performance in a visuospatial delay task 
(delayed response task) to almost the same extent as was produced by surgical ablation of the 
same cortical area. Moreover, the reduced performance was reversed by dopamine receptor 
agonists. A number of more recent studies have shown that mainly dopamine D1, but not D2, 
receptors are involved in the modulation of tasks relying on intact prefrontal cortical 
functioning (Castner et al. 2000; Goldman-Rakic 1996; Sawaguchi and Goldman-Rakic 1994; 
Sawaguchi and Goldman-Rakic 1991; Williams and Goldman-Rakic 1995). Moreover, D1 
receptor density exceeds D2 density by a factor of 10-20 in animal (Camps et al. 1990; Lidow 
et al. 1991) and human (De et al. 1988) cerebral cortex. However, there is evidence that 
cortical D2 receptors are nonetheless involved in working memory performance. Findings in 
healthy volunteers showed that haloperidol impaired performance in the SWM task 
(McCartan et al. 2001). Moreover, the D2 antagonist sulpiride impaired in some (Mehta et al. 
1999, 2004) but not in all (Mehta et al. 2003, 2005) studies working memory performance, 
while the D2 receptor agonist bromocriptine enhanced working memory performance in 
healthy humans (Mehta et al. 2001). In agreement with this finding in humans, systemic 
administration of the D2 receptor agonist quinpirole in monkeys influenced working memory 
performance; while a low dose of quinpirole impaired working memory performance, higher 
doses led to an enhancement (Arnsten et al. 1995). Furthermore, Kimber et al. (1997) 
demonstrated that bromocriptine either enhanced or impaired working memory capacity, 
depending on the baseline performance of the individual subject. Importantly, effects of D2 
receptor agents have only been observed after systemic administration but not after direct 
infusion into prefrontal cortex. In general, there seems not to be a linear relationship between 
working memory functions and dopaminergic mechanisms of the prefrontal cortex, but rather 
an inverted U-shape function, such that both low and high levels of dopamine are associated 
with impaired working memory performance (Dreher et al. 2002; Murphy et al. 1996; 
Robbins 2005; Stewart and Plenz 2006). Our finding that haloperidol impairs working 
memory performance as indexed by reduced strategy formation and enhanced error rates in 
 
the SWM adds some further evidence for the involvement of D2 receptor family in working 
memory. 
 
There are some limitations to the present study. First, a larger number of subjects 
would have been desirable, especially as they were stratified into subgroups. Although the 
statistical analysis was based to a large extent on a priori hypotheses, a large number of 
statistical comparisons were carried out. With a substantially larger sample size, one 
alternative would be to employ principal component analysis (PCA) to reduce the number of 
critical variables. Second, a wider dose range of haloperidol would also be instrumental in 
investigating potential dose-dependent effects. In addition, the assessment of prolactin and 
homovanillic acid (HVA) could have enriched the present study by providing additional 
measures of haloperidol’s impact on dopamine-related functions in individual subjects. 
 
Conclusion: 
Our results show that effects of the typical antipsychotic haloperidol on sensorimotor 
gating as indexed by PPI and sensory gating as indexed by P50 suppression depends highly 
on the baseline gating state in healthy volunteers. This general finding stands in contrast with 
the available literature on gating in patients with schizophrenia, insofar our findings suggest a 
differential role of dopamine D2 receptors especially in the modulation of P50 suppression 
between schizophrenia patients and healthy volunteers. Moreover, we confirmed the 
relationship between PPI and working memory performance in specific cognitive tasks 
relying on prefrontal cortical function, and showed that haloperidol interfered in such 
prefrontal tasks in healthy subjects. The concomitant assessment of PPI and P50 suppression 
in healthy subjects with low gating levels may provide a translational model to elucidate the 
neuronal basis of PPI and P50 suppression deficits and its relation to cognition. Furthermore, 
this approach may provide a useful basis to assess the efficacy of novel treatments for patients 
with schizophrenia in proof of concept studies. 
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